|Year : 2020 | Volume
| Issue : 4 | Page : 293-296
The role of estrogen in breast cancer
Roaa Khadem1, Fatimah Chassab Mahdi2, Karrar AI-Mosawi2, Ali Abdul Hussein S. AL-Janabi1
1 Department of Microbiology, College of Medicine, University of Karbala, Iraq
2 AI-Ammam Al-Hussein Medical City Hospital in Karbala, Iraq
|Date of Submission||19-Apr-2020|
|Date of Acceptance||02-May-2020|
|Date of Web Publication||30-Dec-2020|
Ali Abdul Hussein S. AL-Janabi
Department of Microbiology, College of Medicine, University of Karbala, Karbala
Source of Support: None, Conflict of Interest: None
Estrogen has a significant effect on the development of breast cancer. Its activities in the human body are mainly performed by binding to cellular estrogen receptor (ER). Breast cancer in relate to the presence of ER can be divided into ER-positive and ER-negative breast cancer. The role of estrogen and its receptors in the development of breast cancer will be discussed in this review.
Keywords: Breast cancer, estradiol, estrogen, estrogen receptor
|How to cite this article:|
Khadem R, Mahdi FC, AI-Mosawi K, S. AL-Janabi AA. The role of estrogen in breast cancer. Biomed Biotechnol Res J 2020;4:293-6
| Introduction|| |
Breast cancer is annually registered as the most common type of cancers in women with a high prevalence and incidence rate., It is also responsible for the high rate of mortality among females. Estrogen as one of the human sex hormones has been proved by many studies to be a risk factor for the development of breast cancer, especially in postmenopausal women.,,, The main function of estrogen in the human body is regulating the work of different parts of the reproductive system., Its normal levels are usually higher in female than that of men. The presence of cellular estrogen receptors (ERs) is the key to the physiological action of estrogen., Based on the presence or absence of ER, breast cancer is divided into ER positive and ER negative. ER-positive breast cancer is more common than the ER-negative type.,
| Breast Cancer|| |
Any malignant disease which is simply called cancer takes the name of the organ in which it is developed in the human body. Thus, breast cancer is a type of malignant disease originating in breast tissues through the transformation of some of them into a malignant form. This transformation may result from the effect of genetic and/or environmental factors and is more likely from the genetic effect after the initiation of mutation in essential genes. Breast cancers can develop in both of females and males with the majority in females. Several factors are associated with the development of breast cancer, including age as cancer risk increase with age without obviating the possibility of it developing at younger age,, personal health history as with those who suffer from noninvasive ductal carcinoma,, family history, lack of physical activity, obesity, alcohol consumption, and exposure to radiation.,, Microflora of the human body can also have a role in some cases of breast cancer through their indirect effects on the causative risk factors.
Breast cancer is considered the most common type of cancers among females, especially in the Western world with 1/10 lifetime risk. Approximately one woman from ten is at risk of breast cancer at some point in her life. New cases of breast cancer are dramatically increasing worldwide. It also the second-most common type of cancer responsible for death after lung cancer. In the USA, more than 250,000 new cases were registered in 2017. This number will expect to rise to 276,480 new cases in women and about 2620 cases in men in 2020. Metastatic stage of breast cancer was diagnosed in 154,794 women in the United States in 2017. However, the studies showed that more than 90% of breast cancer is not at metastatic stage at the time of diagnosis. Breast cancer ranked first in the incidence among the females of the Eastern Mediterranean region, and also when males are included and ranked first among the cancer types in Iraq from top five cancers recorded by the WHO in 2009. In Karbala which is an Iraqi province, it also registered as the first ranking type of cancer among females during 8 years (2008–2015). However, Iraqi females of the middle age are the most common age group with breast cancer as concluded from the comparative study of advanced stages of breast cancer comparing 635 Iraqi females and 1305 British females. From 14.3% of females with palpable breast lumps, one third has breast cancer at age 40–49 years. This high rate was also recorded in Karbala province through 8 years surveillance (2008–2015) when the age-specific rate of females with breast cancer was higher at age 40–49 years. From 1172 Iraqi females with breast cancer, the frequency of cancer was higher among unmarried females at younger ages (<50 years) and about 40.5% in advanced stages (III and IV Stages).
Breast cancer can be classified based on histopathological criteria into ductal carcinoma of the milk duct as the most common type, and lobular carcinoma which develops in the lobules and is less common. This classification has recently become less clinically utilized and replaced by a more recent classification that is based on the immunohistochemical characterization for the assessment of hormone receptor status, human epidermal growth factor receptor 2 gene over-expression or amplification and the proliferative fraction. Breast cancer can also progress further to a metastatic disease, where axillary nodes are the most common sites, but distant metastases can also occur in bone and bone marrow as the major locations.
Breast cancer is usually diagnosed based on the histopathological characterization. Molecular methods are widely used nowadays for the diagnosis of breast cancer, because most breast cancer can develop as an effect of alteration in the DNA molecular content by mutation during the lifetime of an individual. Waks and Winer divided breast cancer into three molecular categories depending on the presence or absence either of estrogen and progesterone receptors, human epidermal growth factor and triple-negative (in the absence of all three molecular markers). The three categories comprise hormone receptor-positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple negative (15%).
| Estrogen|| |
Estrogen is a sex hormone in the human body that can found at high level in females and at lower level in males. It mainly secreted by the ovary and placenta in female and under the direct effect of follicle-stimulating hormone and low level of luteinizing hormone from the adrenal cortex in men., Estrogen plays many physiological functions in the human body. Its main functions in the female include the regulation of the reproductive system and secondary sex characteristics as with breast development. It also plays a role in reproductive biology and sexual behavior of males.
There are three main types of estrogen that naturally produced in the human body, including estrone (E1), 17 β-estradiol (E2), and estriol (E3)., Seventeen β-estradiol is the most active type of estrogen with several effective roles in many physiological functions ranging from regulating the activity of reproductive organs to regulating the work of other organs such as cardiovascular, immune, musculoskeletal, and central nervous system.
| Estrogen Receptors|| |
Estrogen can perform its activities through the attachment with specific cellular receptors called ERs, which are related to the large superfamily of nuclear receptors working as ligand-activated transcription factors., Passive diffusion of estrogen through cell and nuclear membrane allows contact with the ER for binding. Complex produced by estrogen ligand binding with receptors will trigger specific sequences in genes responsive to estrogen, which is called estrogen-response elements, work to regulate growth and differentiation of cells., The ER members have mostly similar protein structure which reflects on their performing the same functions. Two conserved regions are recognized in the ER, one called domain C located in the middle of the protein, which binds with DNA, and another called domain E/F in the carboxy-terminal region, which binds with hormones. ER can be found in two types, ERα and ERβ, which are encoded by two distinct genes that can be expressed in the same or different tissues., ERα is the main type with variable regulation of reproduction and physiological activities in the human body, whereas ERβ acts as modulator to the biological activities of ERα. Both ERα and ERβ have 96% identical amino acids in DNA-binding domains, whereas they have only 53% identical amino acids in their ligand-binding domain.
| Estrogen and Breast Cancer|| |
A specific connection between estrogen and breast cancer has been studied for more than 100 years. The presence of high blood level of estrogen in patients with breast cancer is mostly demonstrated by many studies which also proved that estrogen can act as a risk factor for development of breast cancer, especially in postmenopausal women.,,, Estradiol (E2) is the most active type of estrogen through its association with breast cancer development. Clemons and Gross found evidence supporting the hypothesis that estrogen and its metabolites are associated with the initiation and promotion of breast cancer in a complex manner. Catechol estrogen quinone 4 and catechol estrogen-3,4-quinones are estrogen metabolites in the human body that have a role in the initiation of breast cancer through reacting with DNA to induce oncogenic mutation.
The main mechanism of estrogen in causing breast cancer usually begins from the point of estrogen metabolism that releases many estrogen metabolites which trigger a series of genotoxic and mutagenic activities, resulting to the stimulation of tissue growth. These events work with the help of ER, especially ERα, in which its binding to estrogen activates oncogenic growth pathways in breast cancer cells. Thus, genotoxic metabolites of estrogen, as with estradiol, can work together with ERs in the development of breast cancer., However, Yue et al. proposed two hypotheses to support the role of estrogen in the development of breast cancer. The first hypothesis was that estrogen increases cell proliferation through the stimulation of transcription rate mediated by ER, which may increase the rate of genetic errors during DNA replication and finally to elevate the probability of cancer development in breast tissue. The second hypotheses demonstrated that quinone-derivative metabolites of estradiol can react with DNA, leading to the removal of some genetic bases by a depurination process and increasing the mutation rate during repairs of such errors.
In addition to the high level of estrogen, many endocrine-associated factors can be considered risk factors for the development of breast cancer, including high levels of androstenedione and testosterone hormones, conversion of androgens to the estrogens (estrone and estradiol), and elevated urinary levels of estrogens and androgens. Women with greater urinary excretion of estrogen and androgen hormones are considered at risk to have breast cancer. Postmenopausal women are considered a group prone to develop breast cancer as a result of having higher levels of estradiol.,, Thus, the measurement of sex hormones in postmenopausal women can be used as a predictive marker for the diagnosis of breast cancer for up to 16–20 years. Moreover, the concentration of estradiol and estrone is found higher in young women and in those with obesity, smoking (15 cigarettes per day), and alcoholic (20 g alcohol per day).
Depending on the type of ER, breast cancer since 1970 has been divided into two types, ER positive and ER negative. The absence of ER in ER-negative type may result from the suppression of the ER gene that initiates the DNA methylation in CpG island of the ER gene 5' region. However, ER-negative breast cancer is a very active malignant type through its ability to increase the expression of the receptors of p53, cerbB2, and other epidermal growth factors than does ER-positive breast cancer.
A patient with breast cancer is usually shown a variable content of ER. ER positive is mostly found at a high level among patients with breast cancer compared to those with ER negative., Of 234 patients with breast cancer in California, ER positive was found in 208 of them, whereas only 26 had ER negative. This high rate of ER-positive breast cancer in California has been found to have no variable different in the histological type or geographical distribution. ER positive is more often diagnosed as the major type in postmenopausal women with breast cancer (72%) than in premenopausal patients (57%) and the development of this type of ER in postmenopausal women was found to be increased after the treatment with some kinds of estrogen therapy. Otherwise, ER type in combination with progesterone was found positive form in 66.6% of patients with breast cancer, especially in postmenopausal women, whereas negative form was found in 25.2%.
The availability of many factors can be associated with increased the risk for the development of ER-positive breast cancer, such as nulliparity, delayed childbearing, early menarche, and postmenopausal obesity. In the presence of primary ER-negative breast cancer, the risk for the development of contralateral breast cancer can raised compared with those with ER-positive type. Race and age also effects on the presence of ER type when white postmenopausal women at age 75–79 years were shown to be more ER positive than in black premenopausal women at the age of 50 years. On the other hand, Stanford and Greenberg recorded that women with white skin color were more ER positive than black women at the age of 35–54 years and the rate of ER negative can increase with age up to 50–54 years.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Ingvarsson S. Breast cancer: Introduction. Semin Cancer Biol 2001;11:323-6.
Vultaggio V, Mansi L, Fischer U, Baum F, Luftner-Nagel S. Breast cancer: Diagnostic imaging and therapeutic guidance. Eur J Nucl Med Mol Imaging 2018;45:2484.
Hormone Health Network. What does estrogen do? J Clin Endocrinol Metab 2014;99:31A-2.
Clemons M, Gross P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85.
Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, et al
. Genotoxic metabolites of estradiol in breast: Potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 2003;86:477-86.
Onland-Moret NC, Kaaks R, van Noord PA, Rinaldi S, Key T, Grobbee DE, et al
. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer 2003;88:1394-9.
Darbre PD. Disrupters of estrogen action and synthesis. In: Endocrine Disruption and Human Health. Ch. 3. Academic Press. U.S.A: Elsevier Inc. Academic Press; 2015. p. 49-73.
Jones RE, Lopez KH. The male reproductive system. In: Human Reproductive Biology. 4 ed. Academic Press. U.S.A: Elsevier Inc. Academic Press; 2014. p. 67-83.
Yasar P, Ayaz G, User SD, Güpür G, Muyan M. Molecular mechanism of estrogen-estrogen receptor signaling. Reprod Med Biol 2017;16:4-20.
Katzenellenbogen BS. Estrogen receptors: Bioactivities and interactions with cell signaling pathways. Biol Reprod 1996;54:287-93.
Dai X, Xiang L, Li T, Bai Z. Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer 2016;7:1281-94.
Hwang ES, Chew T, Shiboski S, Farren G, Benz CC, Wrensch M. Risk factors for estrogen receptor-positive breast cancer. Arch Surg 2005;140:58-62.
Ramani KV, Ramani H, Alurkar SS, Ajaikumar BS, Trivedi RG. Breast cancer: Medical treatment, side effects, and complementary therapies. In: Human Diseases and Conditions collection. New York: A. Malcolm Campbell, Momentum Press Health; 2017.
Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: What we know and what we need. Nat Med 2001;7:552-6.
Piscuoglio S, Ng CK, Murray MP, Guerini-Rocco E, Martelotto LG, Geyer FC, et al
. The genomic landscape of male breast cancers. Clin Cancer Res 2016;22:4045-56.
Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol 2008;66:65-74.
Chen HL, Zhou MQ, Tian W, Meng KX, He HF. Effect of age on breast cancer patient prognoses: A population-based study using the SEER 18 database. PLoS One 2016;11:e0165409.
Schacht DV, Yamaguchi K, Lai J, Kulkarni K, Sennett CA, Abe H. Importance of a personal history of breast cancer as a risk factor for the development of subsequent breast cancer: Results from screening breast MRI. AJR Am J Roentgenol 2014;202:289-92.
Haber G, Ahmed NU, Pekovic V. Family history of cancer and its association with breast cancer risk perception and repeat mammography. Am J Public Health 2012;102:2322-9.
Alwan NA, Tawfeeq FN, Mallah NA. Demographic and clinical profiles of female patients diagnosed with breast cancer in Iraq. J Contemp Med Sci 2019;5:14-9.
Urbaniak C, Gloor GB, Brackstone M, Scott L, Tangney M, Reid G. The microbiota of breast tissue and its association with breast cancer. Appl Environ Microbiol 2016;82:5039-48.
Waks AG, Winer EP. Breast cancer treatment: A review. JANA 2019;321:288-300.
Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev 2017;26:809-15.
WHO. Towards a Strategy for Cancer Control in the Eastern Mediterranean Region. Document WHO-EM/NCD/060/E/7.09/400; 2009. Available from: http://www.emro.who.int/dsaf/dsa1002.pdf
. [Last accessed on 2020 Mar 13].
AL-Janabi AA. Does histopathological examination still have value in detecting and preventing cancer? Brazilian J Med Hum Health 2017;5:134-43.
Alwan NA, Kerr D, Al-Okati D, Pezella F, Tawfeeq FN. Comparative study on the clinicopathological profiles of breast cancer among Iraqi and British patients. Open Public Health J 2018;11:177-91.
Alwan NA. Breast cancer: Demographic characteristics and clinico-pathological presentation of patients in Iraq. East Mediterr Health J 2010;16:1159-64.
Viale G. The current state of breast cancer classification. Ann Oncol 2012;23:x207-10.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al
. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010;134:e48-72.
Josh H, Press MF. Molecular Oncology of Breast Cancer. 5 ed., Ch. 22. Academic Press. U.S.A: Elsevier Inc; 2018. p. 282-307.
Carroll RG. Female reproductive system. Ch. 14. In: Elsevier's Integrated Physiology. Academic Press. U.S.A; 2007. p. 177-87.
Shoham Z, Schachter M. Estrogen biosynthesis – Regulation, action, remote effects, and value of monitoring in ovarian stimulation cycles. Fertil Steril 1996;65:687-701.
Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, et al
. Mechanisms of estrogen action. Physiol Rev 2001;81:1535-65.
Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, et al
. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: Long-term results of a prospective study. Br J Cancer 2004;90:153-9.
Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, et al
. Endogenous Hormones and Breast Cancer Collaborative Group. Circulating sex hormones and breast cancer risk factors in postmenopausal women: Reanalysis of 13 studies. Br J Cancer 2011;105:709-22.
Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat 2013;137:883-92.
Ferguson AT, Lapidus RG, Baylin SB, Davidson NE. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 1995;55:2279-83.
Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, et al
. Estrogen receptor-negative breast carcinomas: A review of morphology and immunophenotypical analysis. Mod Pathol 2005;18:26-35.
Benz CC, Clarke CA, Moore DH 2nd
. Geographic excess of estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1523-7.
Lower EE, Blau R, Gazder P, Stahl DL. The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer. Breast Cancer Res Treat 1999;58:205-11.
Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, et al
. Poor prognosis of single hormone receptor- positive breast cancer: Similar outcome as triple-negative breast cancer. BMC Cancer 2015;15:138.
Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: A systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13:1558-68.
Reiner AS, Lynch CF, Sisti JS, Jhon EM, Brooks JD, Bernstein L, et al
. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. Breast Cancer Res 2017;19:83.
Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 2002;76:27-36.
Stanford JL, Greenberg RS. Breast cancer incidence in young women by estrogen receptor status and race. Am J Public Health 1989;79:71-3.